Allogene Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • May 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to Goldman Sachs & Co. LLC (the “Underwriter”) an aggregate of 36,896,551 shares of the Company’s common stock, par value $0.001 per share (“Stock”, and such shares, the “Shares”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 13, 2024, between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
